Transcode Therapeutics Inc. (RNAZ)
NASDAQ (CM) NASDAQ (CM) Primary Summary
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?
TransCode Therapeutics (NASDAQ: RNAZ ) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares. TransCode Therapeutics is selling 10 million shares of its common stock for 30 cents each.
Q2 2024 EPS Estimates for TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Decreased by Analyst
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) – Equities research analysts at HC Wainwright reduced their Q2 2024 earnings per share estimates for shares of TransCode Therapeutics in a research report issued on Thursday, May 16th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.58) per share for the quarter, down from their previous estimate of ($0.50). HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($1.98) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.39) EPS, FY2024 earnings at ($1.98) EPS, FY2026 earnings at ($0.47) EPS and FY2028 earnings at ($0.39) EPS. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.15 on Monday. TransCode Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $309.60. The company has a market capitalization of $7.61 million, a P/E ratio of 0.00 and a beta of -0.36. The stock has a 50-day simple moving average of $0.70 and a 200-day simple moving average of $3.73. Institutional Trading of TransCode Therapeutics A hedge fund recently raised its stake in TransCode Therapeutics stock. Sabby Management LLC raised its stake in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Free Report) by 32.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 250,309 shares of the company’s stock after acquiring an additional 61,872 shares during the period. Sabby Management LLC owned approximately 12.33% of TransCode Therapeutics worth $126,000 as of its most recent SEC filing. About TransCode Therapeutics (Get Free Report) TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Read More Five stocks we like better than TransCode Therapeutics Bank Stocks – Best Bank Stocks to Invest In MarketBeat Week in Review – 5/13 – 5/17 How to Use the MarketBeat Dividend Calculator Take-Two Interactive Software Offers 2nd Chance for Investors The Top 3 Healthcare Dividend Stocks to Buy and Hold Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Transcode Therapeutics Inc. (RNAZ) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Transcode Therapeutics Inc. ever had a stock split?
Transcode Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Philippe P. Calais Pharm., CEO | NASDAQ (CM) Exchange | 89357L501 CUSIP |
| US Country | 7 Employees | - Last Dividend | 15 May 2025 Last Split | 8 Jul 2021 IPO Date |
Overview
TransCode Therapeutics, Inc. is a pioneering ribonucleic acid (RNA) oncology company dedicated to the development and commercialization of therapeutic and diagnostic solutions for various forms of cancer. Established in 2016 and headquartered in Boston, Massachusetts, the company is at the forefront of leveraging RNA technology to target and manipulate cancer-causing genes, aiming to transform cancer treatment paradigms. Focused on addressing some of the most challenging aspects of cancer therapy, such as metastasis and resistance to current treatments, TransCode Therapeutics employs cutting-edge RNA-based technologies to develop innovative cancer therapies and diagnostics.
Products and Services
- TTX-MC138
- TTX-siPDL1
- TTX-siLIN28B
- TTX-RIGA
- TTX-CRISPR
- TTX-mRNA
TransCode Therapeutics' flagship therapeutic candidate, TTX-MC138, is designed to target microRNA-10b, identified as a master regulator of metastatic cell viability in several types of cancer, including breast, pancreatic, ovarian, and colon cancers, as well as glioblastomas. By focusing on this microRNA, TTX-MC138 aims to provide a novel approach for treating cancers with high metastatic potential.
This product is an siRNA (small interfering RNA)-based modulator targeting programmed death-ligand 1 (PD-L1). By modulating the expression of PD-L1, TTX-siPDL1 aims to enhance the immune system's ability to recognize and destroy cancer cells, offering a promising approach in the fight against cancer by mobilizing the patient's own immune responses.
Another key development in TransCode's portfolio is TTX-siLIN28B, an siRNA-based inhibitor targeting the RNA-binding protein LIN28B. LIN28B plays a crucial role in the development and progression of various cancers. TTX-siLIN28B seeks to address this by inhibiting LIN28B, thus offering a novel therapeutic strategy for combating cancers associated with this protein.
TTX-RIGA is an RNA-based agonist targeting the retinoic acid-inducible gene I (RIG-I). By activating RIG-I, TTX-RIGA aims to stimulate innate immunity within the tumor microenvironment, thereby enhancing the body's natural defenses against cancer cells. This approach represents an innovative strategy to modify the tumor microenvironment for therapeutic benefit.
TransCode Therapeutics is also exploring the potential of CRISPR/Cas9 technology with TTX-CRISPR, a platform for the repair or elimination of cancer-causing genes directly inside tumor cells. Utilizing the precision of CRISPR/Cas9, TTX-CRISPR aims to offer targeted and personalized cancer therapies by editing the genes responsible for cancer progression.
The TTX-mRNA platform represents an mRNA-based approach for the development of cancer vaccines. By activating cytotoxic immune responses against tumor cells, TTX-mRNA vaccines aim to train the immune system to specifically target and eliminate cancer cells, offering a promising avenue for cancer prevention and treatment through immuno-oncology.
